Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. cut its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 78.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,568 shares of the company's stock after selling 30,936 shares during the quarter. Point72 Asia Singapore Pte. Ltd.'s holdings in Dianthus Therapeutics were worth $235,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of DNTH. Vanguard Group Inc. boosted its stake in shares of Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after buying an additional 384,182 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock valued at $2,095,000 after acquiring an additional 72,509 shares during the period. SG Americas Securities LLC boosted its position in shares of Dianthus Therapeutics by 104.0% during the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after purchasing an additional 4,506 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after purchasing an additional 8,473 shares during the period. Finally, WINTON GROUP Ltd purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $265,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on DNTH shares. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday, August 9th. Finally, Raymond James raised their price target on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded down $0.89 during mid-day trading on Wednesday, reaching $24.68. 157,695 shares of the stock were exchanged, compared to its average volume of 206,979. The business's fifty day simple moving average is $26.60 and its 200 day simple moving average is $26.53. The stock has a market capitalization of $730.45 million, a PE ratio of -9.87 and a beta of 1.74. Dianthus Therapeutics, Inc. has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.